Metis TechBio, a $1B+ AI-Driven Nanomedicine Unicorn, Receives HKEX Listing Approval

Apr 19, 2026 19:40 CST Updated 19:40

METiS TechBio

AI-Driven Drug Formulation Developer

The application of Metis TechBio Co., Ltd. was submitted confidentially on February 12.March 25,METiS TechBio's IPO application document has been made public, with Jefferies, Deutsche Bank Hong Kong Branch, and CITIC CLSA acting as joint sponsors. The company plans to issue no more than 273,495,000 overseas-listed ordinary shares and list them on the Hong Kong Stock Exchange. A total of 39 shareholders intend to convert their combined 851,697,111 unlisted domestic shares into overseas-listed shares for trading on the Hong Kong Stock Exchange. On April 19,METiS TechBio has passed the hearing and is expected to be listed on the Hong Kong stock exchange through an IPO soon.

METiS TechBioMETiS TechBio is a leader in AI-driven nanomaterial innovation, committed to the delivery and application of payloads across all forms of life, adhering to the mission of pioneering a healthier future through AI nanotechnology innovation. Its history dates back to 2020, when it was co-founded by Dr. Lai, Dr. Chen, and Dr. Wang.

METiS TechBioMETiS TechBio is a leader in AI-driven nanomaterial innovation, committed to the delivery and application of payloads across all forms of life, guided by the vision of pioneering a healthier future through AI nanotechnology innovation. Its history dates back to 2020, when it was co-founded by Dr. Lai, Dr. Chen, and Dr. Wang.

July 2025METiS TechBio Completes US$350 Million Series C Financing, Post-money Valuation at US$1.049 Billion. Investors Include CICC (11.4%), 5Y Capital (4.78%), Sequoia China (6.89%), PICC Pension and Health Fund (5.29%), and China Life.Equity 3.68%、Beijing Medical and Health Fund, Daxing Industrial Fund, etc.,Total financing exceeds 2 billion yuan.

NanoForge is the foundation of METiS TechBio's proprietary, synergistically integrated artificial intelligence-driven nanotechnology innovation system, encompassing an autonomously generated extensive lipid library, artificial intelligence foundational models, METiS agents, quantum chemistry and molecular dynamics simulations, and an AI-driven high-throughput screening platform. Based on this,METiS TechBioDeveloped three major professional solutions (namely, the AiTEM, AiLNP, and AiRNA platforms) to simulate, predict, and interpret interactions at the nanoscale, thereby enabling the rational design, optimization, and validation of advanced nanomaterials and their associated payloads.

NanoForge integrates multiple cutting-edge nanodelivery technologies and advanced artificial intelligence techniques. This comprehensive platform enables molecular generation and property prediction, AI-driven iterative processes in dry and wet labs, as well as formulation design and optimization. With a scalable and adaptable design, NanoForge serves as the cornerstone for revolutionizing the discovery and application of nanomaterials in human disease treatment and beyond.

Pipeline of products under development, with over 10 pipeline products, including several candidate products in the discovery stage, 3 preclinical candidates, 3 clinical-stage products, 1 pre-NDA product, and 2 animal health products.

Follow the official account below to explore the world with us!